Gln-AMS (TFA)

• UNSPSC Description:

  Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. Gln-AMS inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.

• Target Antigen:

  Aminoacyl-tRNA Synthetase; Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/Gln-AMS_TFA.html

• Purity:

  99.65

• Solubility:

  DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 130 mg/mL (ultrasonic)

• Smiles:

  NC1=C2N=CN([C@@H]3O[C@H](COS(=O)(NC([C@@H](N)CCC(N)=O)=O)=O)[C@@H](O)[C@H]3O)C2=NC=N1.OC(C(F)(F)F)=O

• Molecular Weight:

  588.47

• References & Citations:

  [1]Rath VL, et al. How glutaminyl-tRNA synthetase selects glutamine. Structure. 1998 Apr 15;6(4):439-49.|[2]Fang P, et al. Structural basis for full-spectrum inhibition of translational functions on a tRNA synthetase. Nat Commun. 2015 Mar 31;6:6402.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported